**SUPPLEMENTARY STATSTICS SUMMARY**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Figure** | **Descriptors** | **n** | **Test used** | **Statistic** | **p-value** |
| S2 - 1f | With direct inhibitionAmplitude (pA)Baseline+NBQX+GZ | 4 | Repeated-measures ANOVA*(log transformed data)*Tukey post hoc test*Baseline vs NBQX**Baseline vs GZ**NBQX vs GZ* | F(2,6) = 7.9t(3) = 0.7t(3) = 4.7t(3) = 3.5 | 0.020.70.0010.002 |
| S2 - 1f | No direct inhibitionAmplitude (pA)Baseline+NBQX+GZ | 8 | Repeated-measures ANOVA*(log transformed data)*Tukey post hoc test*Baseline vs NBQX**Baseline vs GZ**NBQX vs GZ* | F(2,14) = 84.7t(7) = 12.1t(7) = 12.7t(7) = 0.53 | 1.5 x10-80.0010.0010.84 |
|  |  |  |  |  |  |
| S7 - 1b | Pre vs post SalB | vH-BA = 3vH-NAc = 7 | Mixed ANOVAEffect of groupEffect of drugInteraction | F(1,8) = 0.29F(1,8) = 13.8F(1,8) = 0.35 | 0.60.0070.57 |
| S7 - 1c | Pre vs post SalB | vH-BA = 2vH-NAc = 6 | Mixed ANOVAEffect of groupEffect of drugInteraction | F(1,6) = 0.21F(1,6) = 31.3F(1,6) = 0.75 | 0.660.0010.42 |
|  |  |  |  |  |  |